DON in pediatric cerebral malaria, a phase I/IIA dose-escalation safety study: study protocol for a clinical trial.
Nginache Nampota-Nkomba, Osward M Nyirenda, Jane Mallewa...
https://pubmed.ncbi.nlm.nih.gov/38279124/Actively Recruiting
Led by Douglas Postels, MD, MS · Updated on 2026-10-23
152
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effects of a single intravenous dose of 6-diazo-5-oxo-L-norleucine DON in healthy adults, adults with uncomplicated malaria, and children aged 12 months to 14 years with cerebral malaria. This study includes two parts an open-label dose escalation in adults and a randomized, placebo-controlled dose escalation in children with cerebral malaria, aiming to understand safety, pharmacokinetics, and potential effects on brain blood flow, brain volume, and brain activity patterns. In the first part, adult participants receive increasing doses of DON ranging from 0.1 to 10 mgkg intravenously, along with premedication using ondansetron to prevent nausea. Adults with uncomplicated malaria also receive standard antimalarial therapies. In the second part, children with cerebral malaria receive either DON at doses of 0.1 or 1.0 mgkg or placebo, alongside antimalarial treatments, across four cohorts with differing dose and randomization ratios. Pediatric participation spans three malaria seasons, with a total study duration of six months for both adults and children. Participants undergo safety evaluations including monitoring for adverse events and assessments of coma scores. Pharmacokinetic measurements of DON levels are taken up to 18 hours post-infusion. Children with cerebral malaria also have brain blood flow evaluated by transcranial Doppler, brain volume assessed by MRI, and brain activity recorded by EEG. Follow-up and safety monitoring continue for six months after dosing to assess the effects and tolerability of DON.
CONDITIONS
DON in Pediatric Cerebral Malaria
Y
Yamikani Chimalizeni, MD
A
Alice Liomba
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Douglas Postels, MD, MS
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Healthy adults and adults with uncomplicated malaria receive a single intravenous dose of DON at increasing amounts from 0.1 to 10 mg/kg with safety checks before dose increases. Adults receive anti-nausea medication before and after dosing.
Safety evaluations and monitoring visits during the 6 months
Duration - 6 months
Children aged 12 months to 14 years with cerebral malaria receive a single intravenous dose of DON or placebo alongside standard antimalarial treatments. Four cohorts receive different doses and randomization ratios over three malaria seasons.
Regular monitoring and safety assessments throughout the 6 months
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
13
Have more questions? Get in touch with our team for quick support
Nginache Nampota-Nkomba, Osward M Nyirenda, Jane Mallewa...
https://pubmed.ncbi.nlm.nih.gov/38279124/Brittany A Riggle, Athanasios Chamzas, Mathangi Gopalakrishnan...
https://pubmed.ncbi.nlm.nih.gov/41748157/Douglas Postels, MD, MS
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor